Smith M L, Fogelman I, Ralston S, Boyce B F, Boyle I T
Metab Bone Dis Relat Res. 1984;5(4):167-70. doi: 10.1016/0221-8747(84)90024-9.
In Paget's disease of bone, quantitation of skeletal uptake of radiolabeled diphosphonate has been proposed as a means of monitoring response to therapy. However, the validity of such techniques has been questioned during oral diphosphonate therapy because of possible interaction between oral and radiolabeled diphosphonate. In the present study 18 patients with Paget's disease received a 6 month course of oral diphosphonate therapy. Measurements of 24 h whole body retention (WBR) of 99mTc-labeled hydroxyethylidene diphosphonate (HEDP), serum alkaline phosphatase (SAP), and urinary hydroxyproline excretion were obtained before, during, and after treatment. WBR correlated well with SAP and urinary hydroxyproline throughout the course of therapy. In addition, the relationship between WBR and SAP was maintained after cessation of oral diphosphonate. It would thus appear that in Paget's disease 24 h WBR of HEDP, a quantitative measure of skeletal uptake of diphosphonate, will reflect disease activity even in the presence of an oral diphosphonate load.
在骨佩吉特病中,放射性标记双膦酸盐的骨骼摄取定量已被提议作为监测治疗反应的一种方法。然而,由于口服双膦酸盐与放射性标记双膦酸盐之间可能存在相互作用,在口服双膦酸盐治疗期间,此类技术的有效性受到了质疑。在本研究中,18例佩吉特病患者接受了为期6个月的口服双膦酸盐治疗。在治疗前、治疗期间和治疗后,分别测量了99mTc标记的羟基亚乙基二膦酸盐(HEDP)的24小时全身滞留率(WBR)、血清碱性磷酸酶(SAP)以及尿羟脯氨酸排泄量。在整个治疗过程中,WBR与SAP和尿羟脯氨酸均具有良好的相关性。此外,停止口服双膦酸盐后,WBR与SAP之间的关系依然存在。因此,在佩吉特病中,HEDP的24小时WBR作为双膦酸盐骨骼摄取的定量指标,即使在存在口服双膦酸盐负荷的情况下,也能反映疾病活动情况。